{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:20:50Z","timestamp":1787718050188,"version":"build-2784847793"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.07.037","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:22:13Z","timestamp":1785856933000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory B-Cell Lymphoma: A Nationwide Registry Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-9435","authenticated-orcid":false,"given":"Tatsuya","family":"Konishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8021-4732","authenticated-orcid":false,"given":"Wataru","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4405-8808","authenticated-orcid":false,"given":"Shohei","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3142-8806","authenticated-orcid":false,"given":"Masahide","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6373-3442","authenticated-orcid":false,"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Furukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsu","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8043-7768","authenticated-orcid":false,"given":"Nobuharu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-1928","authenticated-orcid":false,"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-4467","authenticated-orcid":false,"given":"Akiyo","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3025-723X","authenticated-orcid":false,"given":"Yasuhiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-5052","authenticated-orcid":false,"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6299-4266","authenticated-orcid":false,"given":"Haryoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-4585","authenticated-orcid":false,"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.jtct.2026.07.037_bib0001","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.037_bib0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1200\/JCO-25-00507","article-title":"Five-year analysis of the JULIET trial of tisagenlecleucel in patients with relapsed\/refractory large B-cell lymphoma","volume":"44","author":"Maziarz","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.037_bib0003","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jtct.2026.07.037_bib0004","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.07.037_bib0005","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.037_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.037_bib0007","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.037_bib0008","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41408-025-01318-5","article-title":"Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma\u2014results from a multicenter cohort study","volume":"15","author":"St-Pierre","year":"2025","journal-title":"Blood Cancer J"},{"issue":"24","key":"10.1016\/j.jtct.2026.07.037_bib0009","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1182\/bloodadvances.2025017873","article-title":"Predictive markers for the efficacy of CAR T-cell therapy: the interplay between CAR T-cell fitness and systemic immunity","volume":"9","author":"Yoo","year":"2025","journal-title":"Blood Adv"},{"issue":"7640","key":"10.1016\/j.jtct.2026.07.037_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jtct.2026.07.037_bib0011","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41574-024-01032-5","article-title":"The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies","volume":"20","author":"Lysaght","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.037_bib0012","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.037_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002349","article-title":"Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors","volume":"9","author":"Ahmed","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.jtct.2026.07.037_bib0014","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.3324\/haematol.2021.280189","article-title":"Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 chimeric antigen receptor T-cell therapy in advanced B-cell malignancies","volume":"107","author":"Dos Santos","year":"2022","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jtct.2026.07.037_bib0015","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"23","key":"10.1016\/j.jtct.2026.07.037_bib0016","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1182\/bloodadvances.2022007676","article-title":"The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes","volume":"6","author":"Faruqi","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.037_bib0017","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s00277-025-06338-6","article-title":"The impact of obesity and its related underlying diseases on cytokine release syndrome and the efficacy of CAR-T therapy in treating B-cell malignancies","volume":"104","author":"Du","year":"2025","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.037_bib0018","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-021-00515-2","article-title":"The impact of obesity and body weight on the outcome of patients with relapsed\/refractory large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"11","author":"Wudhikarn","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.037_bib0019","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/bloodadvances.2024014555","article-title":"Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes","volume":"9","author":"Valtis","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.037_bib0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2026.07.037_bib0021","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","article-title":"Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study","volume":"9","author":"Prado","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.07.037_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106907","article-title":"Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: a systematic review and meta-analysis","volume":"88","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"10.1016\/j.jtct.2026.07.037_bib0023","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-24-3782","article-title":"Sarcopenia and skeletal muscle loss after CAR T-cell therapy in diffuse large B-cell lymphoma","volume":"31","author":"Jhaveri","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.07.037_bib0024","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.jtct.2026.07.037_bib0025","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jcyt.2024.03.481","article-title":"Complex association of body mass index and outcomes in patients with relapsed and refractory multiple myeloma treated with CAR-T cell immunotherapy","volume":"26","author":"Cheng","year":"2024","journal-title":"Cytotherapy"},{"issue":"3","key":"10.1016\/j.jtct.2026.07.037_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.bict.2025.100015","article-title":"Impact of body mass index on anti-BCMA chimeric antigen receptor T-cell therapy outcomes in multiple myeloma","volume":"1","author":"Choa","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.07.037_bib0027","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2026.07.037_bib0028","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0448","article-title":"Outcomes among patients with or without obesity and with cancer following treatment with immune checkpoint blockade","volume":"5","author":"Yoo","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.037_bib0029","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00262-022-03320-3","article-title":"Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade","volume":"72","author":"Jain","year":"2023","journal-title":"Cancer Immunol Immunother"},{"issue":"9403","key":"10.1016\/j.jtct.2026.07.037_bib0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jtct.2026.07.037_bib0031","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2011.2","article-title":"Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index","volume":"1","author":"Lim","year":"2011","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.jtct.2026.07.037_bib0032","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1182\/blood-2025-7682","article-title":"Impact of obesity on outcomes of CAR T-cell therapy for hematologic malignancies: a real-world propensity-matched analysis","volume":"146","author":"Eysha","year":"2025","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2026.07.037_bib0033","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/bloodadvances.2023011433","article-title":"Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?","volume":"8","author":"S\u00e1nchez-Salinas","year":"2024","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:53:37Z","timestamp":1787716417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"alternative-id":["S2666636726006007"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.037","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body Mass Index and Outcomes after CD19 Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory B-Cell Lymphoma: A Nationwide Registry Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.07.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}